Preferred Label : Anti-B7-H3 Antibody-drug Conjugate MGC026;
NCIt synonyms : Anti-B7-H3 ADC MGC026; Anti-B7-H3/Exatecan Antibody-drug Conjugate MGC026; Anti-B7-H3/Exatecan ADC MGC026;
NCIt definition : An antibody-drug conjugate (ADC) composed of vobramitamab, a humanized monoclonal
antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276),
site-specifically conjugated, via a cleavable glycan-based linker, to the camptothecin
analog exatecan, with potential antineoplastic activity. Upon administration of anti-B7-H3
ADC MGC026, the anti-B7-H3 antibody moiety targets and binds to B7-H3-expressing tumor
cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan
inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting
in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of
B7-H3-expressing tumor cells. MGC026 also induces bystander killing activity. B7-H3,
a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily,
is overexpressed on certain tumor cell types and on various immune cells while its
expression is limited on healthy cells. It is a negative regulator of T-cell activation
and its overexpression plays a key role in tumor cell invasion and metastasis.;
Molecule name : MGC-026; MGC 026;
NCI Metathesaurus CUI : CL1928510;
Origin ID : C206214;
concept_is_in_subset
- has_target
